Puma Biotechnology - decided to allow Leaks Listed by ragnarlocker Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

In August 2022, people connected to Puma Biotechnology faced the possibility that internal company files had been taken in a ransomware incident and placed at risk of public release. When a biotech firm’s internal material is claimed as stolen, the practical concern is straightforward: employees, partners, contractors, and others whose details sit inside those systems may find personal or professional information circulating beyond the organisation’s control, with little public clarity on exactly who or what was involved.

Public reporting at the time indicated that the ragnarlocker ransomware group had listed Puma Biotechnology on its leak site and claimed to have exfiltrated internal data. The number of people affected remains unknown, and independent confirmation of the full scope has not been laid out in the available record. What matters for those potentially touched by the incident is understanding what is known, what is only claimed, and what steps can reduce downstream risk.

Inside the incident

According to reporting dated 2 August 2022, Puma Biotechnology appeared on the leak site operated by the ragnarlocker ransomware group. The group claimed to have stolen internal data in a ransomware attack and indicated that leaks would be allowed. The available facts describe the exposed material as internal files exfiltrated in that attack. No verified figure for the number of people affected has been published, and details such as the precise method of intrusion, the volume of data, specific file names, or any ransom demand are not disclosed in the public summary.

The listing itself is a claim by the group rather than an independently confirmed inventory of what was taken or released. Organisations named on ransomware leak sites sometimes negotiate, sometimes refuse, and sometimes see partial or full data dumps follow; the record here states only that the company was listed and that the group asserted it had obtained internal files. Timing beyond the 2 August 2022 report date, and any subsequent confirmation or denial by the company, are not part of the provided facts.

Inside ragnarlocker

RagnarLocker is a ransomware operation that has been publicly documented since at least 2020. Like many groups in this category, it has typically combined encryption of victim systems with data theft, then used a dedicated leak site to pressure organisations by threatening to publish stolen material if demands are not met. The group has been associated with attacks across multiple sectors, often focusing on mid-sized and larger enterprises where disruption and reputational exposure create leverage.

Public reporting on RagnarLocker has described the use of double-extortion tactics: encrypting files while also exfiltrating copies, then advertising the victim on a dark-web blog. Affiliates or operators have historically sought to move quickly, sometimes abusing legitimate remote-administration tools and known vulnerabilities to gain footholds. None of that general pattern should be read as a verified playbook for this specific incident; it simply situates the actor whose leak-site listing is the source of the claim against Puma Biotechnology. The group’s assertion that it stole internal data from this victim remains, on the available facts, an unverified claim.

About Puma Biotechnology

Puma Biotechnology is a biopharmaceutical company. Organisations in this sector develop and commercialise therapies, run clinical and regulatory processes, and maintain extensive internal records covering research, partnerships, employees, and business operations. They routinely hold sensitive commercial information, correspondence with regulators and collaborators, and personal data belonging to staff and sometimes to patients or trial participants through related systems.

A breach or claimed exfiltration at such a firm is consequential because the data environment mixes intellectual property, contractual material, and personal information. Even when the precise contents of a theft are unconfirmed, the sector’s reliance on confidential development pipelines and regulated personal data means that unauthorised access can affect individuals far beyond the company’s own payroll, including partners and anyone whose identifiers appear in internal files.

The information in question

The facts state that internal files were exfiltrated in a ransomware attack and that the group claims to have stolen internal data. No further breakdown of data types—such as employee records, financial documents, research files, or contact lists—is provided. Exact contents therefore remain unconfirmed.

Companies of this kind typically maintain human-resources files, email and messaging archives, contracts, research and regulatory documentation, and vendor or partner information. Any of those categories could in principle appear among “internal files,” but it would be inaccurate to treat them as established elements of this incident. Public detail is limited to the characterisation already given: internal files claimed as stolen and listed in connection with a ransomware leak-site entry.

What's at stake

For individuals, the real-world risks centre on misuse of whatever personal or professional details may have been inside the taken files. That can include targeted phishing that references internal projects or colleagues, identity-related fraud if identifiers or contact data were present, and longer-term exposure if material is published or traded. Because the number of people affected is unknown and the file inventory is undisclosed, no one outside the investigation can say with certainty whether a given person is included; the prudent stance is to treat the possibility seriously until clearer information emerges.

For the organisation, stakes include operational disruption from the ransomware event itself, potential regulatory and contractual obligations around data protection, and reputational harm if internal material surfaces. None of these outcomes is asserted here as having already materialised beyond the leak-site listing; they are the ordinary consequences that follow when internal files are claimed as stolen in this manner.

If your data was in this claimed breach

If you have a past or present connection to Puma Biotechnology—as an employee, contractor, partner, or in another capacity—consider taking a few measured steps while public detail remains limited:

• Treat unexpected messages that reference the company, internal projects, or colleagues with caution; verify through known official channels before responding or clicking.
• Monitor financial and account statements for unfamiliar activity and enable stronger authentication on important email and work-related accounts where available.
• If you receive notification from the company or a regulator, follow the specific instructions in that notice rather than relying solely on general advice.
• Preserve any relevant correspondence and consider a credit or fraud alert if you later learn that sensitive personal identifiers were involved.

You can also run a free exposure scan of your email address to check whether your information has already surfaced in known breach data sets. That check will not confirm or deny inclusion in this specific incident, but it can show whether the same address appears elsewhere in circulated breach material and help you prioritise further protections.

AICompiled with AI assistance from public sources and published under our editorial standards.